The Psychedelics Newsletter

Ceruvia on the mechanism of migraine, Psych Capital to list on Aquis Stock Exchange, US federal agency awards US$2.7m to develop psychedelic medicines.

PSYCH Symposium: London 2022, CSIRO shows support for psychedelic healthcare, Inside the dispute over a high-profile psychedelic study

EXCLUSIVE: Biomind Labs' relocation to the UK, Psychedelic research in the UK and Europe, Brain-scanning technology to test efficacy of psychedelic medicine.

Negev Capital and Investing in Psychedelic Healthcare, Landmark gathering of psychedelic executives and scientists in London, Marketing the future of healthcare

MindMed, MM-120 and Dynamic Drug Development; Making psilocybin available to UK cancer patients; Oregon to only allow cultivation of psilocybe cubensis.

Bicycle Day; Are psychedelic stocks reaching the bottom as bad investors bail?; MindMed to present clinical trial results at PSYCH Symposium

Mental health and psychedelic medicine, Numinus Wellness acquires Novamind for C$26.2m, Psilocybin increases brain connectivity for up to three weeks

Filament Health and naturally extracted psychedelic medicines, New species of hallucinogenic mushroom discovered in Australia, Psychedelic medicines may ease cancer patients' depression.

COMPASS Pathways and COMP360 psilocybin therapy, The Centre for Mental Health Research and Innovation launches in the UK, Why Dr. Bronner’s is offering ketamine therapy to employees.

Accessing psilocybin in the UK, Inside London's first psychedelic psychotherapy clinic, California activists drop 2022 psilocybin legalisation initiative.

DMT and Major Depressive Disorder, Psilocybin dispensaries operating openly in Vancouver, Johns Hopkins, Yale and New York University collaborate on psychiatrist training.

Two days left for PSYCH Symposium Early Bird Tickets, Novamind to host Phase II psilocybin trial, Demand grows for UK ministers to reclassify psilocybin.